Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on April 4, 2019. The report details a material definitive agreement entered into on April 4, 2019, and other events occurring on April 5, 2019.
Key Financial Metrics and Transaction Details
The filing describes a registered direct offering and a concurrent private placement with Lincoln Park Capital Fund, LLC.
- Gross Proceeds: Approximately $1.5 million.
- Securities Issued: 225,813 shares of Common Stock and 156,353 Series A warrants.
- Purchase Price: $3.925 per Share or Series A Warrant.
- Series A Warrants: Exercise price of $0.01 per share; exercisable immediately; expire 5 years from issuance.
- Series B Warrants (Private Placement): Issued for each Share and Series A Warrant purchased; exercise price of $3.80 per share; exercisable 6 months after issuance; expire 5.5 years from issuance.
The filing does not provide specific data on revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Restrictions
As part of the Purchase Agreement, the Company agreed to a 60-day lock-up period following the closing. During this period, the Company will not issue or agree to issue any shares of Common Stock or Common Stock equivalents, subject to certain exceptions.
Outlook, Risks, and Other Events
On April 5, 2019, the Company issued a press release announcing updated data following a presentation at the American Association for Cancer Research. The filing notes that the Series B Warrants and related shares are unregistered and offered pursuant to Section 4(a)(2) and Rule 506(b) exemptions. The filing text does not provide specific management commentary on future guidance, risks, or contingencies beyond the transaction terms.
Investor Verification Checklist
- Verify the exact closing date and final net proceeds after deducting offering expenses.
- Review the definitive Purchase Agreement (Exhibit 10.1) for specific exceptions to the 60-day lock-up restriction.
- Examine the press release (Exhibit 99.2) for details on the updated clinical data presented at the American Association for Cancer Research.
- Confirm the dilution impact of the Series A and Series B warrants on existing shareholders.